UBS AM’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q3 | – | Sell |
-78,954
| Closed | -$1.42M | – | 2532 |
|
|
2020
Q2 | $1.42M | Sell |
78,954
-6,378
| -7% | -$88.7K | ﹤0.01% | 1657 |
|
|
2020
Q1 | $608K | Buy |
85,332
+7,611
| +10% | +$95K | ﹤0.01% | 1900 |
|
|
2019
Q4 | $1.86M | Buy |
77,721
+6,145
| +9% | +$170K | ﹤0.01% | 1635 |
|
|
2019
Q3 | $1.92M | Buy |
71,576
+19,343
| +37% | +$543K | ﹤0.01% | 1629 |
|
|
2019
Q2 | $1.42M | Sell |
52,233
-266,318
| -84% | -$8.35M | ﹤0.01% | 1753 |
|
|
2019
Q1 | $11.1M | Sell |
318,551
-34,529
| -10% | -$996K | 0.01% | 904 |
|
|
2018
Q4 | $6.89M | Buy |
353,080
+25,900
| +8% | +$533K | 0.01% | 970 |
|
|
2018
Q3 | $8.71M | Sell |
327,180
-11,610
| -3% | -$379K | 0.01% | 971 |
|
|
2018
Q2 | $12.8M | Sell |
338,790
-23,865
| -7% | -$913K | 0.01% | 886 |
|
|
2018
Q1 | $11.8M | Sell |
362,655
-12,883
| -3% | -$565K | 0.01% | 891 |
|
|
2017
Q4 | $18.3M | Buy |
375,538
+92,409
| +33% | +$4.67M | 0.02% | 771 |
|
|
2017
Q3 | $15.3M | Buy |
283,129
+7,062
| +3% | +$415K | 0.01% | 802 |
|
|
2017
Q2 | $15.5M | Sell |
276,067
-123,617
| -31% | -$4.95M | 0.02% | 800 |
|
|
2017
Q1 | $15.7M | Buy |
399,684
+96,962
| +32% | +$3.09M | 0.02% | 788 |
|
|
2016
Q4 | $6.79M | Sell |
302,722
-14,894
| -5% | -$291K | 0.01% | 935 |
|
|
2016
Q3 | $7.21M | Sell |
317,616
-156
| -0% | -$3.66K | 0.01% | 947 |
|
|
2016
Q2 | $7.5M | Sell |
317,772
-11,542
| -4% | -$285K | 0.01% | 936 |
|
|
2016
Q1 | $6.72M | Buy |
329,314
+129,793
| +65% | +$4.12M | 0.01% | 951 |
|
|
2015
Q4 | $10.3M | Sell |
199,521
-6,540
| -3% | -$317K | 0.01% | 855 |
|
|
2015
Q3 | $8.78M | Buy |
206,061
+120,264
| +140% | +$5.8M | 0.01% | 901 |
|
|
2015
Q2 | $3.91M | Buy |
85,797
+68,897
| +408% | +$2.77M | ﹤0.01% | 1129 |
|
|
2015
Q1 | $642K | Buy |
16,900
+7,400
| +78% | +$254K | ﹤0.01% | 1835 |
|
|
2014
Q4 | $269K | Buy |
9,500
+1,300
| +16% | +$36.1K | ﹤0.01% | 2298 |
|
|
2014
Q3 | $207K | Buy |
8,200
+1,100
| +15% | +$29K | ﹤0.01% | 2367 |
|
|
2014
Q2 | $207K | Buy |
+7,100
| New | +$172K | ﹤0.01% | 2394 |
|
UBS AM's PTLA Position: Q3 2020 in Review
UBS AM sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q3 2020, closing a stake of 78,954 shares — an estimated $1.42M sold.
UBS AM first reported a position in PTLA in Q2 2014 and held it in 25 quarters. The position peaked at $18.3M in Q4 2017. 0 funds tracked by Wall St. Rank hold PTLA as of Q3 2020.
- UBS AM reported no remaining Portola Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
- UBS AM sold 78,954 Portola Pharmaceuticals, Inc. shares in Q3 2020, an estimated $1.42M.
- UBS AM first reported a position in Portola Pharmaceuticals, Inc. in Q2 2014 and held it in 25 quarters.
- UBS AM's Portola Pharmaceuticals, Inc. position peaked at $18.3M in Q4 2017.
- 0 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q3 2020.
Based on UBS AM's 13F filing for Q3 2020, filed 13 Nov 2020.